[go: up one dir, main page]

NO20032149D0 - Nye anvendelser av kombinerte, selektive dopamin D2- reseptorantagonister og5-HT1A-reseptoragonister - Google Patents

Nye anvendelser av kombinerte, selektive dopamin D2- reseptorantagonister og5-HT1A-reseptoragonister

Info

Publication number
NO20032149D0
NO20032149D0 NO20032149A NO20032149A NO20032149D0 NO 20032149 D0 NO20032149 D0 NO 20032149D0 NO 20032149 A NO20032149 A NO 20032149A NO 20032149 A NO20032149 A NO 20032149A NO 20032149 D0 NO20032149 D0 NO 20032149D0
Authority
NO
Norway
Prior art keywords
new applications
selective dopamine
combined selective
ht1a
receptor antagonists
Prior art date
Application number
NO20032149A
Other languages
English (en)
Other versions
NO20032149L (no
Inventor
Gerd Bartoszyk
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO20032149D0 publication Critical patent/NO20032149D0/no
Publication of NO20032149L publication Critical patent/NO20032149L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
NO20032149A 2000-11-14 2003-05-13 Nye anvendelser av kombinerte, selektive dopamin D2- reseptorantagonister og5-HT1A-reseptoragonister NO20032149L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00124814 2000-11-14
PCT/EP2001/012325 WO2002039988A2 (en) 2000-11-14 2001-10-25 Novel uses of combined selective dopamine d2 receptor antagonists and 5-ht1a receptor agonists

Publications (2)

Publication Number Publication Date
NO20032149D0 true NO20032149D0 (no) 2003-05-13
NO20032149L NO20032149L (no) 2003-05-13

Family

ID=8170368

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032149A NO20032149L (no) 2000-11-14 2003-05-13 Nye anvendelser av kombinerte, selektive dopamin D2- reseptorantagonister og5-HT1A-reseptoragonister

Country Status (18)

Country Link
US (1) US20040014788A1 (no)
EP (1) EP1333821A2 (no)
JP (1) JP2004513915A (no)
KR (1) KR20030065511A (no)
CN (1) CN1474688A (no)
AR (1) AR035503A1 (no)
AU (1) AU2002221744A1 (no)
BR (1) BR0115297A (no)
CA (1) CA2428519A1 (no)
CZ (1) CZ20031434A3 (no)
HU (1) HUP0302761A2 (no)
MX (1) MXPA03004249A (no)
NO (1) NO20032149L (no)
PL (1) PL361462A1 (no)
RU (1) RU2283648C2 (no)
SK (1) SK6392003A3 (no)
WO (1) WO2002039988A2 (no)
ZA (1) ZA200304602B (no)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2009131C2 (en) * 2012-07-05 2014-01-07 Stichting Vu Vumc Compound and use of compound to prepare a radiollabelled compound.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0465254B1 (en) * 1990-07-06 1996-11-13 Yoshitomi Pharmaceutical Industries, Ltd. Fused thiophene compounds and uses thereof
US5314888A (en) * 1992-02-21 1994-05-24 Trustees Of Tufts College Veterinary method for treating inappropriate elimination of urine in household pets
GB9302622D0 (en) * 1993-02-10 1993-03-24 Wellcome Found Heteroaromatic compounds
IL114027A (en) * 1994-06-08 1999-11-30 Lundbeck & Co As H 4-Phenyl piperazine (piperidine or tetrahydropyridine) derivatives serotinin 5-HT1A and dopamin D2 receptor ligand pharmaceutical compositions containing them
DE69524528T2 (de) * 1994-10-14 2002-08-01 Merck Patent Gmbh ZNS wirksames (R)-(-)-2-[5-(4-Fluorophenyl)-3-pyridylmethylaminomethyl]chroman
US5554383A (en) * 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
AU6517196A (en) * 1995-07-13 1997-02-10 Knoll Aktiengesellschaft Piperazine derivatives as therapeutic agents
GB9514380D0 (en) * 1995-07-13 1995-09-13 Knoll Ag Therapeutic agents
EP0900792B1 (en) * 1997-09-02 2003-10-29 Duphar International Research B.V Piperazine and piperidine derivatives as 5-HT1A and dopamine D2-receptor (ant)agonists
ATE253058T1 (de) * 1997-09-02 2003-11-15 Duphar Int Res Piperidin- und piperazin derivate als 5-ht1- rezeptor-agonisten
AU2981099A (en) * 1998-03-09 1999-09-27 Trustees Of Tufts College Treatment of compulsive behaviours in man and animals
EP1076647A2 (en) * 1998-04-29 2001-02-21 American Home Products Corporation Antipsychotic indolyl derivatives
UA71590C2 (en) * 1998-11-13 2004-12-15 Duphar Int Res Piperazine and piperidine derivatives

Also Published As

Publication number Publication date
AU2002221744A1 (en) 2002-05-27
CN1474688A (zh) 2004-02-11
BR0115297A (pt) 2003-08-26
ZA200304602B (en) 2004-09-13
EP1333821A2 (en) 2003-08-13
CA2428519A1 (en) 2002-05-23
JP2004513915A (ja) 2004-05-13
HUP0302761A2 (hu) 2003-12-29
US20040014788A1 (en) 2004-01-22
AR035503A1 (es) 2004-06-02
WO2002039988A2 (en) 2002-05-23
PL361462A1 (en) 2004-10-04
SK6392003A3 (en) 2003-11-04
MXPA03004249A (es) 2003-09-22
KR20030065511A (ko) 2003-08-06
NO20032149L (no) 2003-05-13
WO2002039988A3 (en) 2002-07-25
CZ20031434A3 (cs) 2003-09-17
RU2283648C2 (ru) 2006-09-20

Similar Documents

Publication Publication Date Title
NO20032797L (no) Substituerte pyridoindoler som serotonin agonister og antagonister
NO20041817L (no) Arylanilin beta-2-adrenergisk reseptoragonister
NO20040933L (no) Nye gamma-sekretaseinhibitorer.
IS6566A (is) Indólín-2-ón afleiður, framleiðsla og notkun þeirra sem mjaltavaka (ocytocin) viðtakabindlar
DK1257275T3 (da) Anvendelse af en antagonist til centrale cannabiboidreceptorer til fremstilling af lægemidler, der er nyttige for at göre det lettere at ophöre med brug af tobak
NO20040014L (no) Nye forbindelser
NO20015113D0 (no) Nye forbindelser, deres fremstilling og anvendelse
NO20041003L (no) Nye forbindelser
NO20034665L (no) Nye forbindelser
IS6802A (is) 3-arýlindólafleiður og notkun þeirra sem CB2 viðtakagerandefni
NO20034970D0 (no) Nye arylheteroalkylaminderivater
NO20041008L (no) Karbazolderivater og anvendelse derav som NPY5 reseptor antagonister
NO20034773D0 (no) Nye ftalazinoner
DK1355639T3 (da) Substituerede carbostyrilderivater som 5-HT1A-receptorsubtypeagonister
NO20004271D0 (no) Benzylpiperazinyl- og benzylpiperidinyl etanonderivater, deres fremstilling og deres anvendelse som dopamin D4 reseptorantagonister
ATE381541T1 (de) Aminotetralinderivate, antagonisten von muscarinrezeptoren
DE60038911D1 (de) 4-Phenylpiperazinyl, -piperidinyl und -tetrahydropyridyl-Derivate als Dopamin D4-Antagonisten
DE60238709D1 (de) 4-piperidinylalkylamin-derivate, antagonisten von muscarinrezeptoren
NO20013709L (no) Nye N-triazolylmetyl-piperazinderivater som neurokininreseptor-antagonister
NO20020644D0 (no) Nye integrinreseptor-antagonister
NO20032149L (no) Nye anvendelser av kombinerte, selektive dopamin D2- reseptorantagonister og5-HT1A-reseptoragonister
DE60131556D1 (de) Ringnetzwerk und datensender
NO20032148L (no) Nye anvendelser av kombinerte 5-HT1A-agonister og serotoningjenopptaksinhibitorer
NO20025461D0 (no) Nye formuleringer av <alfa>-(2,4-disulfofenyl)-N-tert- butylnitron
DE60236848D1 (de) 8-ä4-Ä3-(5-FLUORO-1H-INDOL-3-YL)PROPYLÜ -1-PIPERAZINYLü -2-METHYL-2H-1, 4-BENZOXAZIN-3(4H)-ON METHANESULFONAT MIT HOHER AFFINITÄT FÜR DEN DOPAMIN D2 REZEPTOR UND DEN SEROTONIN REUPTAKE SITE

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application